Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores
Background Rheumatoid arthritis (RA) is a prevalent inflammatory disorder causing functional disabilities. Oxidative stress can cause inflammation and can also be induced by inflammation. Measuring oxidative stress markers could help better understand the pathophysiology of RA and may be used to def...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2021-10, Vol.40 (10), p.4019-4026 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4026 |
|---|---|
| container_issue | 10 |
| container_start_page | 4019 |
| container_title | Clinical rheumatology |
| container_volume | 40 |
| creator | Najafizadeh, Seyed Reza Amiri, Khatereh Moghaddassi, Maryam Khanmohammadi, Shaghayegh Mirmiranpour, Hossein Nakhjavani, Manouchehr |
| description | Background
Rheumatoid arthritis (RA) is a prevalent inflammatory disorder causing functional disabilities. Oxidative stress can cause inflammation and can also be induced by inflammation. Measuring oxidative stress markers could help better understand the pathophysiology of RA and may be used to define the disease severity.
Material and method
In this case–control study, 75 RA patients were selected among those referred to the rheumatology clinic. Patients were further categorized into two groups, with active and inactive disease according to the Disease Activity Score (DAS) 28. Forty healthy volunteered persons were selected as the control group. Blood samples were obtained, and advanced glycation end products (AGEs), advanced oxidation protein products (AOPPs), and ferric reducing ability of plasma (FRAP) were measured. The results were compared via student t-test and Chi-square.
Results
Mean ± SD values for AGEs, AOPP, and FRAP in cases and controls were 53.29 ± 6.82 vs. 44.43 ± 7.13 (p = 0.001), 146.08 ± 19.56 vs. 135.79 ± 14.23 (p = 0.004), and 967.13 ± 226.66 vs. 1012.87 ± 215.94 (p = 0.2), respectively. Mean ± SD values for AGEs, AOPP, and FRAP in patients with active disease and inactive disease were 53.32 ± 7.2 vs. 53.26 ± 6.48 (p = 0.9), 146.97 ± 17.56 vs. 145.06 ± 21.84 (p = 0.6), and 953.17 ± 217.09 vs. 983.09 ± 239.31 (p = 0.5), respectively.
Conclusion
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls. There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease.
Key points
•
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls.
•
There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease |
| doi_str_mv | 10.1007/s10067-021-05771-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2534611119</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2534611119</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-a47fb39c20fd69d64b663a01700ff73145cd2c19b5905287235fc7e71b19bb5c3</originalsourceid><addsrcrecordid>eNp9kctuHCEQRVEUSxk_fiArpGyycDs8m8E7y8pLspRNvEY0jxmsHhgDbbs_Kv8YJm0rkRdhAVJx7q0qXQDeY3SBERKfSrt70SGCO8SFwN38Bqwwo6yTksm3YIWEQB3Fcv0OHJdyhxAia4lX4NeVfdDROAs342x0DSlCFy3c52QnU8s51C9Aegp2AdpndSH-CzWJdzkHA7NrtRA3UA9hDHWGycP9qMtOw4OkObhYC3wMdQvz1k07XVOwUOe6zaGGcgk19MlMBbZO2tTwcDApJmVXTsGR12NxZ8_vCbj98vnn9bfu5sfX79dXN52hnNROM-EHKg1B3vbS9mzoe6oRFgh5Lyhm3FhisBy4RJysBaHcG-EEHlpt4IaegI-Lb9vwfnKlql0oxo2jji5NRRFOWY_bkQ398Aq9S1OObbpGiR4jxvi6UWShTE6lZOfVPoedzrPCSB0SVEuCqiWo_iSo5iaii6g0OG5c_mv9H9VvmXOigw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2576104458</pqid></control><display><type>article</type><title>Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores</title><source>SpringerLink Journals</source><creator>Najafizadeh, Seyed Reza ; Amiri, Khatereh ; Moghaddassi, Maryam ; Khanmohammadi, Shaghayegh ; Mirmiranpour, Hossein ; Nakhjavani, Manouchehr</creator><creatorcontrib>Najafizadeh, Seyed Reza ; Amiri, Khatereh ; Moghaddassi, Maryam ; Khanmohammadi, Shaghayegh ; Mirmiranpour, Hossein ; Nakhjavani, Manouchehr</creatorcontrib><description>Background
Rheumatoid arthritis (RA) is a prevalent inflammatory disorder causing functional disabilities. Oxidative stress can cause inflammation and can also be induced by inflammation. Measuring oxidative stress markers could help better understand the pathophysiology of RA and may be used to define the disease severity.
Material and method
In this case–control study, 75 RA patients were selected among those referred to the rheumatology clinic. Patients were further categorized into two groups, with active and inactive disease according to the Disease Activity Score (DAS) 28. Forty healthy volunteered persons were selected as the control group. Blood samples were obtained, and advanced glycation end products (AGEs), advanced oxidation protein products (AOPPs), and ferric reducing ability of plasma (FRAP) were measured. The results were compared via student t-test and Chi-square.
Results
Mean ± SD values for AGEs, AOPP, and FRAP in cases and controls were 53.29 ± 6.82 vs. 44.43 ± 7.13 (p = 0.001), 146.08 ± 19.56 vs. 135.79 ± 14.23 (p = 0.004), and 967.13 ± 226.66 vs. 1012.87 ± 215.94 (p = 0.2), respectively. Mean ± SD values for AGEs, AOPP, and FRAP in patients with active disease and inactive disease were 53.32 ± 7.2 vs. 53.26 ± 6.48 (p = 0.9), 146.97 ± 17.56 vs. 145.06 ± 21.84 (p = 0.6), and 953.17 ± 217.09 vs. 983.09 ± 239.31 (p = 0.5), respectively.
Conclusion
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls. There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease.
Key points
•
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls.
•
There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-021-05771-y</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Advanced glycosylation end products ; Glycosylation ; Inflammatory diseases ; Medicine ; Medicine & Public Health ; Original Article ; Oxidation ; Oxidative stress ; Rheumatoid arthritis ; Rheumatology</subject><ispartof>Clinical rheumatology, 2021-10, Vol.40 (10), p.4019-4026</ispartof><rights>International League of Associations for Rheumatology (ILAR) 2021. corrected publication 2021</rights><rights>International League of Associations for Rheumatology (ILAR) 2021. corrected publication 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-a47fb39c20fd69d64b663a01700ff73145cd2c19b5905287235fc7e71b19bb5c3</citedby><cites>FETCH-LOGICAL-c352t-a47fb39c20fd69d64b663a01700ff73145cd2c19b5905287235fc7e71b19bb5c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-021-05771-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-021-05771-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Najafizadeh, Seyed Reza</creatorcontrib><creatorcontrib>Amiri, Khatereh</creatorcontrib><creatorcontrib>Moghaddassi, Maryam</creatorcontrib><creatorcontrib>Khanmohammadi, Shaghayegh</creatorcontrib><creatorcontrib>Mirmiranpour, Hossein</creatorcontrib><creatorcontrib>Nakhjavani, Manouchehr</creatorcontrib><title>Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><description>Background
Rheumatoid arthritis (RA) is a prevalent inflammatory disorder causing functional disabilities. Oxidative stress can cause inflammation and can also be induced by inflammation. Measuring oxidative stress markers could help better understand the pathophysiology of RA and may be used to define the disease severity.
Material and method
In this case–control study, 75 RA patients were selected among those referred to the rheumatology clinic. Patients were further categorized into two groups, with active and inactive disease according to the Disease Activity Score (DAS) 28. Forty healthy volunteered persons were selected as the control group. Blood samples were obtained, and advanced glycation end products (AGEs), advanced oxidation protein products (AOPPs), and ferric reducing ability of plasma (FRAP) were measured. The results were compared via student t-test and Chi-square.
Results
Mean ± SD values for AGEs, AOPP, and FRAP in cases and controls were 53.29 ± 6.82 vs. 44.43 ± 7.13 (p = 0.001), 146.08 ± 19.56 vs. 135.79 ± 14.23 (p = 0.004), and 967.13 ± 226.66 vs. 1012.87 ± 215.94 (p = 0.2), respectively. Mean ± SD values for AGEs, AOPP, and FRAP in patients with active disease and inactive disease were 53.32 ± 7.2 vs. 53.26 ± 6.48 (p = 0.9), 146.97 ± 17.56 vs. 145.06 ± 21.84 (p = 0.6), and 953.17 ± 217.09 vs. 983.09 ± 239.31 (p = 0.5), respectively.
Conclusion
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls. There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease.
Key points
•
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls.
•
There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease</description><subject>Advanced glycosylation end products</subject><subject>Glycosylation</subject><subject>Inflammatory diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Oxidation</subject><subject>Oxidative stress</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kctuHCEQRVEUSxk_fiArpGyycDs8m8E7y8pLspRNvEY0jxmsHhgDbbs_Kv8YJm0rkRdhAVJx7q0qXQDeY3SBERKfSrt70SGCO8SFwN38Bqwwo6yTksm3YIWEQB3Fcv0OHJdyhxAia4lX4NeVfdDROAs342x0DSlCFy3c52QnU8s51C9Aegp2AdpndSH-CzWJdzkHA7NrtRA3UA9hDHWGycP9qMtOw4OkObhYC3wMdQvz1k07XVOwUOe6zaGGcgk19MlMBbZO2tTwcDApJmVXTsGR12NxZ8_vCbj98vnn9bfu5sfX79dXN52hnNROM-EHKg1B3vbS9mzoe6oRFgh5Lyhm3FhisBy4RJysBaHcG-EEHlpt4IaegI-Lb9vwfnKlql0oxo2jji5NRRFOWY_bkQ398Aq9S1OObbpGiR4jxvi6UWShTE6lZOfVPoedzrPCSB0SVEuCqiWo_iSo5iaii6g0OG5c_mv9H9VvmXOigw</recordid><startdate>20211001</startdate><enddate>20211001</enddate><creator>Najafizadeh, Seyed Reza</creator><creator>Amiri, Khatereh</creator><creator>Moghaddassi, Maryam</creator><creator>Khanmohammadi, Shaghayegh</creator><creator>Mirmiranpour, Hossein</creator><creator>Nakhjavani, Manouchehr</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20211001</creationdate><title>Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores</title><author>Najafizadeh, Seyed Reza ; Amiri, Khatereh ; Moghaddassi, Maryam ; Khanmohammadi, Shaghayegh ; Mirmiranpour, Hossein ; Nakhjavani, Manouchehr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-a47fb39c20fd69d64b663a01700ff73145cd2c19b5905287235fc7e71b19bb5c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Advanced glycosylation end products</topic><topic>Glycosylation</topic><topic>Inflammatory diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Oxidation</topic><topic>Oxidative stress</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Najafizadeh, Seyed Reza</creatorcontrib><creatorcontrib>Amiri, Khatereh</creatorcontrib><creatorcontrib>Moghaddassi, Maryam</creatorcontrib><creatorcontrib>Khanmohammadi, Shaghayegh</creatorcontrib><creatorcontrib>Mirmiranpour, Hossein</creatorcontrib><creatorcontrib>Nakhjavani, Manouchehr</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Najafizadeh, Seyed Reza</au><au>Amiri, Khatereh</au><au>Moghaddassi, Maryam</au><au>Khanmohammadi, Shaghayegh</au><au>Mirmiranpour, Hossein</au><au>Nakhjavani, Manouchehr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><date>2021-10-01</date><risdate>2021</risdate><volume>40</volume><issue>10</issue><spage>4019</spage><epage>4026</epage><pages>4019-4026</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Background
Rheumatoid arthritis (RA) is a prevalent inflammatory disorder causing functional disabilities. Oxidative stress can cause inflammation and can also be induced by inflammation. Measuring oxidative stress markers could help better understand the pathophysiology of RA and may be used to define the disease severity.
Material and method
In this case–control study, 75 RA patients were selected among those referred to the rheumatology clinic. Patients were further categorized into two groups, with active and inactive disease according to the Disease Activity Score (DAS) 28. Forty healthy volunteered persons were selected as the control group. Blood samples were obtained, and advanced glycation end products (AGEs), advanced oxidation protein products (AOPPs), and ferric reducing ability of plasma (FRAP) were measured. The results were compared via student t-test and Chi-square.
Results
Mean ± SD values for AGEs, AOPP, and FRAP in cases and controls were 53.29 ± 6.82 vs. 44.43 ± 7.13 (p = 0.001), 146.08 ± 19.56 vs. 135.79 ± 14.23 (p = 0.004), and 967.13 ± 226.66 vs. 1012.87 ± 215.94 (p = 0.2), respectively. Mean ± SD values for AGEs, AOPP, and FRAP in patients with active disease and inactive disease were 53.32 ± 7.2 vs. 53.26 ± 6.48 (p = 0.9), 146.97 ± 17.56 vs. 145.06 ± 21.84 (p = 0.6), and 953.17 ± 217.09 vs. 983.09 ± 239.31 (p = 0.5), respectively.
Conclusion
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls. There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease.
Key points
•
AGEs and AOPP but not FRAP were significantly increased in RA patients compared to healthy controls.
•
There was no significant difference between AGEs, AOPP, and FRAP in RA patients with active and inactive disease</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s10067-021-05771-y</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2021-10, Vol.40 (10), p.4019-4026 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2534611119 |
| source | SpringerLink Journals |
| subjects | Advanced glycosylation end products Glycosylation Inflammatory diseases Medicine Medicine & Public Health Original Article Oxidation Oxidative stress Rheumatoid arthritis Rheumatology |
| title | Advanced glycation end products, advanced oxidation protein products, and ferric reducing ability of plasma in patients with rheumatoid arthritis: a focus on activity scores |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T01%3A53%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advanced%20glycation%20end%20products,%20advanced%20oxidation%20protein%20products,%20and%20ferric%20reducing%20ability%20of%20plasma%20in%20patients%20with%20rheumatoid%20arthritis:%20a%20focus%20on%20activity%20scores&rft.jtitle=Clinical%20rheumatology&rft.au=Najafizadeh,%20Seyed%20Reza&rft.date=2021-10-01&rft.volume=40&rft.issue=10&rft.spage=4019&rft.epage=4026&rft.pages=4019-4026&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-021-05771-y&rft_dat=%3Cproquest_cross%3E2534611119%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2576104458&rft_id=info:pmid/&rfr_iscdi=true |